vs
Side-by-side financial comparison of National Bank Holdings Corp (NBHC) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $126.8M, roughly 1.4× National Bank Holdings Corp). National Bank Holdings Corp runs the higher net margin — 16.4% vs 1.6%, a 14.8% gap on every dollar of revenue. Over the past eight quarters, National Bank Holdings Corp's revenue compounded faster (14.0% CAGR vs -0.2%).
Old National Bank is an American regional bank with nearly 200 retail branches operated by Old National Bancorp and based in Chicago and Evansville, Indiana. With assets at $48.5 billion and 250 banking centers, Old National Bancorp is the largest financial services bank holding company headquartered in Indiana and one of the top 30 banking companies in the U.S. Old National Bank has locations in Illinois, Indiana, Iowa, Kentucky, Michigan, Minnesota, Tennessee, and Wisconsin.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
NBHC vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $126.8M | $177.4M |
| Net Profit | $20.8M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | — | 3.9% |
| Net Margin | 16.4% | 1.6% |
| Revenue YoY | — | 5.0% |
| Net Profit YoY | -14.2% | — |
| EPS (diluted) | $0.46 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $126.8M | $177.4M | ||
| Q4 25 | $100.6M | $196.9M | ||
| Q3 25 | $108.9M | $179.5M | ||
| Q2 25 | $104.5M | $181.1M | ||
| Q1 25 | $102.1M | $168.9M | ||
| Q4 24 | $101.3M | $187.3M | ||
| Q3 24 | $106.0M | $168.6M | ||
| Q2 24 | $97.6M | $178.0M |
| Q1 26 | $20.8M | $2.9M | ||
| Q4 25 | $16.0M | — | ||
| Q3 25 | $35.3M | $5.4M | ||
| Q2 25 | $34.0M | $-4.8M | ||
| Q1 25 | $24.2M | $4.8M | ||
| Q4 24 | $28.2M | — | ||
| Q3 24 | $33.1M | $-143.5M | ||
| Q2 24 | $26.1M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 19.0% | 1.2% | ||
| Q3 25 | 39.6% | 3.5% | ||
| Q2 25 | 39.8% | 4.7% | ||
| Q1 25 | 29.2% | 1.2% | ||
| Q4 24 | 34.3% | 13.2% | ||
| Q3 24 | 37.6% | -82.8% | ||
| Q2 24 | 32.5% | 15.9% |
| Q1 26 | 16.4% | 1.6% | ||
| Q4 25 | 15.9% | — | ||
| Q3 25 | 32.4% | 3.0% | ||
| Q2 25 | 32.6% | -2.7% | ||
| Q1 25 | 23.7% | 2.8% | ||
| Q4 24 | 27.8% | — | ||
| Q3 24 | 31.2% | -85.1% | ||
| Q2 24 | 26.8% | 10.6% |
| Q1 26 | $0.46 | $0.07 | ||
| Q4 25 | $0.42 | $0.05 | ||
| Q3 25 | $0.92 | $0.12 | ||
| Q2 25 | $0.88 | $-0.11 | ||
| Q1 25 | $0.63 | $0.10 | ||
| Q4 24 | $0.72 | $0.38 | ||
| Q3 24 | $0.86 | $-3.11 | ||
| Q2 24 | $0.68 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $472.8M | $144.3M |
| Total DebtLower is stronger | $202.1M | — |
| Stockholders' EquityBook value | $1.7B | $653.9M |
| Total Assets | $12.6B | $1.2B |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $472.8M | $144.3M | ||
| Q4 25 | $417.1M | $238.4M | ||
| Q3 25 | $555.6M | $246.3M | ||
| Q2 25 | $296.5M | $445.9M | ||
| Q1 25 | $246.3M | $493.6M | ||
| Q4 24 | $127.8M | $484.6M | ||
| Q3 24 | $180.8M | $453.8M | ||
| Q2 24 | $145.0M | $404.2M |
| Q1 26 | $202.1M | — | ||
| Q4 25 | $54.5M | $372.2M | ||
| Q3 25 | $54.7M | $376.7M | ||
| Q2 25 | $54.4M | $580.5M | ||
| Q1 25 | $54.6M | $583.4M | ||
| Q4 24 | $54.5M | $585.3M | ||
| Q3 24 | $54.4M | — | ||
| Q2 24 | $54.4M | — |
| Q1 26 | $1.7B | $653.9M | ||
| Q4 25 | $1.4B | $693.1M | ||
| Q3 25 | $1.4B | $727.2M | ||
| Q2 25 | $1.4B | $757.8M | ||
| Q1 25 | $1.3B | $798.5M | ||
| Q4 24 | $1.3B | $778.3M | ||
| Q3 24 | $1.3B | $749.6M | ||
| Q2 24 | $1.2B | $879.3M |
| Q1 26 | $12.6B | $1.2B | ||
| Q4 25 | $9.9B | $1.3B | ||
| Q3 25 | $10.2B | $1.3B | ||
| Q2 25 | $10.0B | $1.5B | ||
| Q1 25 | $10.1B | $1.6B | ||
| Q4 24 | $9.8B | $1.6B | ||
| Q3 24 | $10.0B | $1.5B | ||
| Q2 24 | $10.0B | $1.6B |
| Q1 26 | 0.12× | — | ||
| Q4 25 | 0.04× | 0.54× | ||
| Q3 25 | 0.04× | 0.52× | ||
| Q2 25 | 0.04× | 0.77× | ||
| Q1 25 | 0.04× | 0.73× | ||
| Q4 24 | 0.04× | 0.75× | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.04× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NBHC
| Net Interest Income | $108.8M | 86% |
| Noninterest Income | $18.0M | 14% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
